Home / Going-concern warnings / Cellectar Biosciences, Inc.
Filed 2025-11-13 路 Form 10-Q 路 Accession 0001104659-25-110827 nano
Price before filing: $3.5 (2025-11-12 close, split/dividend-adjusted)
Market cap at flag: $4.3M (2025-11-13) 路 Latest: $13.9M (2026-10-16)
| Window | CLRB | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | -8.6% | -0.4% | -8.2% | 2025-12-15 |
| 90 days | -5.4% | +1.6% | -7.0% | 2026-02-11 |
| 180 days | -16.6% | +8.6% | -25.2% | 2026-05-12 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
"These uncertainties raise substantial doubt about the Company's ability to continue as a going concern."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Source: management disclosure in Form 10-Q (period 2025-09-30)
Why this score: quarterly (unaudited) disclosure
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Newsletter delivered by beehiiv. See our privacy policy.